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ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN 
PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY 
BREAST CANCER CAN BE COST-EFFECTIVE FROM ITALIAN, SPANISH, 
AND PORTUGUESE HEALTH-CARE PERSPECTIVES, BASED ON THE 
ABCSG-12 TRIAL
Taneja C1, Delea TE2, Kaura S3, Sternini P4, Gerzeli S5, Gnant M6
1PAI, Brookline, MA, USA; 2Policy Analysis Inc., Brookline, MA, USA; 3Novartis 
Pharmaceuticals Corporation, Florham Park, NJ, USA; 4Novartis Oncology, Origgio, Italy; 
5University of Pavia, Pavia, Italy; 6Medical University of Vienna, Vienna, Austria
OBJECTIVES: To retrospectively estimate the cost-effectiveness of adding zoledronic 
acid (ZOL; 4 mg intravenously q6m) to adjuvant endocrine therapy (ET; goserelin 
plus tamoxifen or anastrozole) in premenopausal women with endocrine-responsive 
early breast cancer (ERBC) from Italian, Spanish, and Portuguese health-care perspec-
tives. METHODS: A Markov model projected lifetime outcomes and costs of care for 
ERBC patients receiving 3 years’ adjuvant ET or adjuvant ET plus ZOL. Cost-effec-
tiveness was measured as the incremental cost per quality-adjusted life-year (QALY) 
gained. Probabilities of BC recurrence were from the ABCSG-12 trial. Other probabili-
ties and country-speciﬁ c costs were from published literature. Results were generated 
under two scenarios: 1) beneﬁ ts of ZOL persist to the 7-year maximum follow-up 
(trial beneﬁ t); 2) beneﬁ ts persist until recurrence or death (lifetime beneﬁ t). RESULTS: 
Expected ZOL costs (medication and administration) were c1500 (Italy), c2100 
(Spain), and c2300 (Portugal). Under the trial beneﬁ t scenario, resulting savings from 
reduced BC recurrence partially offset costs by c900 (both Spain and Italy) and c200 
(Portugal). Therefore, projected total ZOL costs were c600 (Italy), c1300 (Spain), and 
c2100 (Portugal). Projected QALY gains with ZOL were 0.46 (Italy), 0.47 (Spain), 
and 0.33 (Portugal). Costs per QALY gained were c1304 (Italy), c2766 (Spain), and 
c6364 (Portugal) (all favorable). Under the lifetime beneﬁ t scenario, savings from 
reduced BC recurrences completely offset ZOL costs and yielded net savings of c2900 
(Italy) and c2100 (Spain). Incremental total costs were c1400 for Portugal. Projected 
QALY gains with ZOL were 1.57 (Italy), 1.59 (Spain), and 0.96 (Portugal). The cost 
per QALY gained for Portugal was highly favorable (c1458). CONCLUSIONS: 
Adding ZOL to ET in premenopausal women with ERBC can be highly cost-effective 
(<c50,000 per QALY gained) in Italy, Spain, and Portugal. Additionally, ZOL would 
be considered cost saving to patients in Italy and Spain if these beneﬁ ts persist >7 
years.
PCN75
COMPARISON OF ADVANCED NONINVASIVE TECHNIQUES TO 
SCREEN COLORECTAL CANCER: FECAL IMMUNOCHEMICAL TEST VS. 
FECAL DNA; A COS-EFFECTIVENESS STUDY
Bhattacharya R, Shah J, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: This study aims to compare the guaiac-based fecal immunochemical 
test (FIT), the primary colorectal cancer (CRC) detection technique, with the fecal 
DNA (F-DNA) test which has been recommended as an alternative to FIT as the 
standard of care. METHODS: A hybrid decision tree-Markov model was created to 
estimate the CRC screening cost per quality-adjusted life-year (QALYs) of using the 
FIT annually, or the F-DNA every 3, or the F-DNA every 5 years in individuals at 
average CRC risk from a third-party payer’s perspective. a hypothetical cohort of 
10,000, 50-year-old individuals transitioning between the health states: healthy, 
polyps <10 mm, polyps >10 mm, local cancer, regional cancer, advanced cancer, and 
dead, were followed until they were 75 years. Colonoscopy followed every positive 
test result. Sensitivity, speciﬁ city, transition probabilities, and costs (in 2010 US 
Dollars) were obtained from clinical trials and published peer-reviewed articles. The 
costs and QALYs were discounted at 3% and sensitivity analyses were conducted. 
RESULTS: Using FIT annually would result in an average cost of $56,716.94/QALY 
for each individual with an incremental cost-effectiveness ratio (ICER) of $76,181/
QALY when compared to F-DNA used every 5 years. In the ICER plane of 1000 
Monte Carlo simulations, FIT was more costly but more effective technique compared 
to F-DNA used every 5 years, in 77% of the samples. FIT was the most cost-effective 
screening strategy at willingness to pay (WTP) of $100,000/QALY. However, at a 
lower WTP of $50,000/QALY, F-DNA every 5 years was cost-effective until a thresh-
old of $71,000/QALY. F-DNA conducted every 3 years was completely dominated 
by FIT. CONCLUSIONS: Further research is needed, and third-party payers may need 
to assess variables such as compliance and patient characteristics, before considering 
the F-DNA as a standard of care for screening CRC.
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A SIMULATION MODELLING APPROACH TO QUANTIFY THE 
COST-EFFECTIVENESS OF EXTRA-CORPOREAL PHOTOPHERESIS IN 
CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) IN SPAIN
Perez-Simon J1, Sierra J2, Crespo C3, Rodríguez J4 Brosa M3
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OBJECTIVES: Chronic graft-versus-host disease (cGVHD) is a major complication 
after allogeneic hematopoietic stem cell transplantation (HSCT) that impairs quality 
of life, functional status, and long-term survival. There is no standard therapy for 
patients whose cGVHD does not resolve with immunosuppressors and corticosteroid 
treatment. The aim of this study was to compare the cost-effectiveness of extra-cor-
poreal photopheresis (ECP) with Rituximab (Rmb) or Imantinib (IMT) or pooled 
comparators (pooled) in addition to the usual care of cGvHD after standard treatment 
failure in Spain. METHODS: The model assessed the incremental cost-effectiveness 
ratio (ICER) of ECP versus Rmb or IMT or pooled comparator. The incremental cost 
and quality-adjusted life-year (QALY) gained were estimated using a short-term deci-
sion analysis and a long-term Markov cohort modeling approach. Model probabilities 
were obtained from literature, while treatment pathways and adverse event where 
derived from expert opinion. Local data on health resources use and costs were used 
and validated by clinical experts. The time horizon of the study was 5 years and only 
direct local medical costs (euros 2010) were considered. a probabilistic sensitivity 
analysis was performed. RESULTS: Preliminary results show that the higher efﬁ cacy 
of ECP leads to a gain of 0.19–0.20 QALY at ﬁ rst year and 0.15–0.19 at year 5 when 
compared to Rmb or IMT or pooled. The short-term cost of ECP is higher than Rmb 
(c2.900), IMT (c800) and pooled (c1.800). The ICER results for ECP for the ﬁ rst year 
were c15,340 versus RMB, c3.663 verus IMT and c8.977 versus pooled. At 3 years, 
ECP was dominant versus IMT and pooled, and showed ICER less than c3.000 vs. 
Rmb. The results of the evaluation were sensitive to limited data available. CONCLU-
SIONS: Preliminary results of this study indicate ECP is a cost-effective, below the 
Spanish threshold, or dominant option with respect altenatives.
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COST-EFFECTIVENESS OF OCTREOTIDE LAR IN PATIENTS WITH 
METASTATIC NEUROENDOCRINE MIDGUT TUMORS FROM THE 
PRIVATE PAYER PERSPECTIVE IN BRAZIL
Takemoto ML1, Fernandes RA1, Chinen R2, Alves MR2
1ANOVA—Knowledge Translation, Rio de Janeiro, RJ, Brazil; 2Novartis Pharmaceuticals, São 
Paulo, SP, Brazil
OBJECTIVES: Octreotide LAR has shown antiproliferative activity in advanced 
midgut neuroendocrine tumors (NET) increasing time to tumor progression (TTP) 
compared to placebo. This study aims to assess the costs and consequences of OCT-LA 
versus best supportive care (BSC) in patients with metastatic midgut NET from the 
private payer perspective. METHODS: A three health state (progression-free survival, 
progression, and death) Markov model with a 10-year time horizon was developed 
with data from the phase III PROMID trial. Within the trial, subjects remained on 
treatment until progression. Resource use was estimated through published data and 
input from clinical experts to reﬂ ect clinical practice in the Brazilian private setting. 
Unit costs were obtained from Brazilian ofﬁ cial sources. Costs and outcomes were 
discounted 5% per annum. RESULTS: The model estimated 14 months PFS with 
OCT-LA versus 6 months with BSC. Estimated PFS gain was 0.60 years (1.07 vs. 
0.46). Total cost of treatment was 275,497 BRL for BSC and 303,111 BRL for 
OCT-LA. The incremental cost per progression-free year gained was 28,706 BRL in 
the OCT-LA arm versus BSC due to treatment until progression. The mean cost of 
supportive care for progressive disease represented 87.3% (239,883 BRL) and 76.9% 
(224,388 BRL) of the ﬁ nal cost of treatment for BSC and OCT-LA, respectively. 
Results remained consistent when univariate sensitivity analyses were run. CONCLU-
SIONS: OCT-LA is a clinically effective option to control tumor growth in patients 
with metastatic midgut NET. OCT-LA provides longer TTP compared to BSC for 
those patients. Although there is ecological evidence to suggest improvement in OS 
after introduction of OCT LA, the ICER for an additional life-year gained is not cur-
rently calculable as the PROMID trial was not designed to evaluate OS. Further areas 
of research to elucidate the association between PFS and OS in NET are needed.
PCN78
OST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH 
IMATINIB MESYLATE IN PATIENTS AFTER RESECTION OF LOCALIZED 
PRIMARY GASTROINTESTINAL STROMAL TUMOR
Krysanov I, Zorin N, Pyadushkina E, Koval DA
Institute of Clinico-Economic Expertise and Pharmacoeconomics, RSMU, Moscow, Russia
OBJECTIVES: Imatinib is a low molecular tyrosine kinase inhibitor that blocks the 
kinase activity KIT and PDGFRα, and a ﬁ rst-line drug in the treatment of unresectable 
and metastatic gastrointestinal stromal tumor (GIST). The standard treatment of 
patients with localized primary GIST is a complete surgical resection of the tumor. 
Several studies have shown that target therapy improves survival of patients after GIST 
resection. The purpose of this study was to estimate the costs and effectiveness of 
adjuvant imatinib therapy versus no treatment in patients who have undergone GIST 
resection. METHODS: A Markov model was used to estimate costs and effectiveness 
of adjuvant imatinib therapy in the long-term follow-up period. Data on overall and 
recurrence-free survival were taken from the phase III clinical trial ACOSOG Z9001 
and were used to assess efﬁ cacy. Measures of effectiveness include such indicators as 
life-years saved and quality-adjusted life-years (QALYs) gained for adjuvant imatinib 
following surgical resection and surgical resection only. Data on the common practice 
of GIST treatment in the Russian oncology centers were used in the model. Costs, 
life-years, and QALYs gained were calculated over the 50-year time horizon and 
discounted at an annual rate of 5%. RESULTS: The number of life-years saved was 
10.01 for imatinib treatment against 8.67 for no treatment. The number of QALYs 
was 7.97 and 6.82, respectively. The costs of 1-year patient management with adju-
vant imatinib therapy were c44,348 per person; a patient who had not received 
imatinib in adjuvant mode required c32,102 per person. CONCLUSIONS: The analy-
sis showed that adjuvant imatinib therapy is more costly compared with no treatment. 
However, it is more effective and can increase the life expectancy of patients. In this 
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case, the costs of therapy are partly offset by reducing the frequency of relapses and 
the progression of the disease.
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ECONOMIC MODELING FOR TREATMENT FAILURE PATIENTS USING 
MULTIPLE ROUNDS OF THERAPY AS COMPARATOR
Aggarwal S1, Stevens CA2
1PAREXEL Consulting, Bethesda, MD, USA; 2PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: Treatment failure patients in various disease areas are often treated by 
multiple rounds of therapy. However, new treatment options are emerging that have 
potential to replace that treatment with single-agent or single round of combination 
treatment. It is challenging to demonstrate cost-effectiveness of these new agents, 
especially when comparator is not one single regimen but sequential treatment. We 
present here our results from a study where we developed a model that can incorporate 
multiple rounds of treatment or relapses to estimate cost-effectiveness of new emerging 
therapies. METHODS: Intervention was chosen as an emerging T-cell lymphoma drug 
candidate. Comparator was chosen as sequential treatment with 1–5 chemo regimens 
(called DHAP, ESHAP, ICE, HyperCVAD, and EPOCH). All comparator chemo regi-
mens are generics and their prices were obtained from Medispan’s PriceRx. Interven-
tion’s price was assumed as median price of branded chemotherapy agents. Cost, 
efﬁ cacy, adverse events, and utilities were sourced and estimated from published 
studies for T and B-cell lymphoma. Relapses and number of chemo regimens for 
comparators were varied from 1–5. Sensitivity analyses were performed for all base 
calculations. RESULTS: Model results show that a new agent that can replace multiple 
rounds of treatment is relatively more cost-effective than another agent that replaces 
relatively fewer rounds of treatments. Our base-case incremental cost-effectiveness 
with one chemo regimen as comparator was $262,908. However, if there are 2,3,4, 
or 5 sequential rounds, the ICER values change to $223,078, $183,249, $143,420, 
and $103,591, respectively. CONCLUSIONS: For newer agents that are indicated for 
treatment failure patients, the use of sequential treatments as comparator can signiﬁ -
cantly improve their cost-effectiveness. The model approach described here can be 
used for arthritis, hepatitis C, and diabetes and oncology TF patients.
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COST-EFFECTIVENESS ANALYSIS OF OXLIPLATIN IN ADJUVANT 
THERAPY FOR STAGE 3 COLON CANCER PATIENTS IN JAPAN
Fukuda T1, Shiroiwa T2, Takeuchi T1, Shimozuma K2, Ohashi Y1
1Tokyo University, Tokyo, Japan; 2Ritsumeikan University, Kusatsu, Shiga, Japan
OBJECTIVES: FOLFOX (folic acid [l-LV], 5-FU, and oxaliplatin) is a standard 
therapy for metastatic colorectal cancer. FOLFOX in adjuvant therapy was approved 
in 2009. However, cost-effectiveness of FOLFOX, which can prolong DFS (disease-
free survival), is not known. METHODS: We performed cost-effectiveness analysis of 
FOLFOX in adjuvant therapy for stage3 colon cancer compared with FU/LV as a 
standard regimen. Our analysis is based on the patient-level data of MOSAIC (the 
Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adju-
vant Treatment of Colon Cancer) trial. Survival curve of DFS and OS (overall survival) 
was extrapolated by cure model, which uses parametric regression considering some 
patients can cure without recurrence. Death of any other causes was treated as compet-
ing risk. Expected value of mean survival year was gained by calculating area under 
the estimated survival curve during 15 years. QALY (quality-adjusted life-year) was 
calculated weighting survival time by utility scores. Since our analysis is from the 
perspective of health-care payer, only direct medical costs were included. Three percent 
annual discount rate was used for both costs and outcome. RESULTS: Adjuvant 
FOLFOX therapy for stage 3 colon cancer patients can gain more QALY than stan-
dard FU/LV therapy. The difference of both therapies is about 0.5 QALY. ICER 
(incremental cost-effectiveness ratio) of FOLFOX compared with FU/LV estimated to 
be less than JPY 2.5 million (US$28,000, US$ 1 = JPY 90) per QALY. This value is 
thought to be a little conservative because time horizon of our analysis is 15 years, 
not lifetime to avoid uncertainty of long-term future. CONCLUSIONS: FOLFOX 
therapy in adjuvant of stage 3 colon cancer is cost-effective. The ICER compared with 
FU/LV is acceptable from the Japanese health-care payer.
PCN81
COST-EFFECTIVENESS ANALYSIS OF THREE STRATEGIES OF 
ERLOTINIB TREATMENT IN NON0-SMALL-CELL LUNG CANCER: A 
PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
Borget I1, Cadranel J2, Mauguen A1, Coudert B3, Dansin E4, Friard S5, Daniel C6, Quoix E7, 
Madelaine J8, Madroszyk A9, Morin F10, Pignon JP1, Chouaid C11
1Institut Gustave Roussy, Villejuif, France; 2Hospital Tenon, PARIS, France; 3CLCC Dijon, 
Dijon, France; 4CHU Lille, Lille, France; 5Hospital Foch, Suresnes, France; 6Institut Curie, Paris, 
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OBJECTIVES: Although several clinical and biological parameters are prognostic 
factors of NSCLC patients outcome, their medico-economic impact in the prescription 
of erlotinib has never been evaluated. a French NCI prospective study aimed to 
compare cost and effectiveness of three strategies of erlotinib initiation in second line 
or more treatment of advanced NSCLC patients: initiation in all patients, patients 
selected on clinical-guided strategy, and patients selected on biological-guided strategy. 
METHODS: A Markov model compared the outcomes and costs (limited to direct 
medical costs from the third-party payer perspective) of a prospective multicentric 
cohort of consecutive advanced NSCLC patients newly treated by erlotinib, to a cohort 
of clinical-selected patients (non/ex-smoking women with adenocarcinoma histology) 
and a cohort of biomarker-selected patients (EGFR mutation). Utility data were 
extracted from literature. Sensitivity analyses were performed. RESULTS: A total of 
522 patients were enrolled between March 2007 and March 2008. Median age was 
63 years; 32% were females; 65% had adenocarcinoma; and 8% had EGFR mutation. 
The strategy which consists to treat all patients was dominated, as it was both the less 
effective and the most expensive strategy (0.495 QALY/c22,396). The clinical-guided 
strategy was slightly more effective than the biological-guided strategy (respectively 
0.568 and 0.563 QALY), but it was also more expensive (respectively c16,299 and 
c15,187). The dominant strategy was then the biological-guided strategy (c26,975/
QALY). The model was robust to variations of biological exam costs, palliative costs, 
and utility data. Biological-guided strategy appears the most effective and the less 
expensive strategy when the prevalence of EGFR mutation exceeds 10%. CONCLU-
SIONS: Biological-guided strategy appears the dominant strategy if the prevalence of 
EGFR mutation was >10%. This suggests determining EGFR mutation status in prior-
ity to non/former smokers, females with adenocarcinoma.
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RESEARCH PRIORITIZATION FOR PROSPECTIVE COMPARATIVE 
EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS
Veenstra D1, Thariani R1, Carlson JJ1, Garrison L2, Mohr P3, Deverka P4, Tunis SR3, 
Hoban C5, Baker LH5, Ramsey S6
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OBJECTIVES: The Center for Comparative Effectiveness Research in Cancer Genom-
ics (CANCERGEN) is a multidisciplinary, national consortium established to conduct 
CER in Genomics and Personalized Medicine (GPM). The objective was the evaluation 
and prioritization of GPM applications for study in a prospective, randomized CER 
trial. METHODS: Candidate GPMs were identiﬁ ed through a landscape analysis of 
recent literature. Initial candidates were examined by cancer genomics experts and 
study investigators to identify 5–7 GPMs for evaluation by a diverse group of external 
stakeholders, including representatives from patients groups, payers, test developers, 
state-funded public HTA programs, and practicing oncologists. We developed Topic 
Briefs and Test Target Proﬁ les assessing the following domains: population impact, 
current standard of care, clinical validity, potential beneﬁ ts, potential harms, economic 
impact, evidence of need, trial feasibility, and current payer status. RESULTS: We 
identiﬁ ed 43 studies from 183 GPMs based on our landscape analysis, which were 
narrowed to four GPMs through feedback from cancer genomics experts; two addi-
tional GPMs were identiﬁ ed by investigators from our clinical trials consortium 
(SWOG). The six GPMs included: ERCC1 testing for platinum chemotherapy in 
NSCLC, EGFR mutation testing for TKIs in NSCLC maintenance, tumor markers for 
breast cancer recurrence, EGFR FISH testing for ﬁ rst-line cetuximab in NSCLC, BRAF 
testing in colorectal cancer, and gene expression proﬁ ling in multiple myeloma. Exter-
nal stakeholders preliminarily identiﬁ ed the ﬁ rst three of these as most likely providing 
the greatest value of research. CONCLUSIONS: A rapid process for research priori-
tization involving literature evaluation, expert input, and stakeholder feedback is 
feasible with adequate resources and processes. Elements include an organization 
facilitating collaboration between investigators with CER/clinical trials experience, 
and utilizing systematic and timely evidence-assessment accessible to stakeholders. 
Final selection of a GPM for study in a prospective CER trial will be based on quan-
titative value-of-information analyses, implementation feasibility, and funding mecha-
nisms, including coverage with evidence development.
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A COST-EFFECTIVENESS ANALYSIS (CEA) FOR DENOSUMAB, A FULLY 
HUMAN MONOCLONAL ANTIBODY FOR CANCER TREATMENT-
INDUCED BONE LOSS (CTIBL) IN NON-METASTATIC PROSTATE 
CANCER (PRCA): A SWEDISH PERSPECTIVE
Shroff S1, Martin M1, Kearney M2, Lothgren M2, Bracco A2
1i3 Innovus, Uxbridge, Middlesex, UK; 2Amgen (Europe) GmbH, Zug, Switzerland
BACKGROUND: Androgen deprivation therapy (ADT) decreases bone mineral 
density (BMD), increasing risk of fragility fractures and decreasing quality of life over 
time. Until recently, there were no licensed treatments despite high unmet medical 
need. In a randomized, double-blind, placebo-controlled trial, denosumab increased 
BMD and reduced the incidence of vertebral fractures in nonmetastatic PrCa patients 
receiving ADT. OBJECTIVES: To assess the cost-effectiveness (CE) of denosumab 
versus no treatment in nonmetastatic PrCa CTIBL patients in Sweden. METHODS: 
A Markov model was adapted from previously developed models in osteoporosis. This 
includes six fracture states: hip, vertebral, wrist, other, post-hip, and post-vertebral 
fracture. Model inputs were based on a literature review conducted in PUBMED. The 
target population reﬂ ected patient characteristics of the trial. The model horizon was 
5 years, reﬂ ecting progression to metastatic disease. General population fracture risks 
from Swedish males were adjusted by the relative risk of fracture due to ADT. Only 
the efﬁ cacy of denosumab on vertebral fractures was included in the base case. a 
societal perspective was used. Published trial data were used to validate the model in 
terms of fractures. RESULTS: The cost per QALY (ICER) for denosumab versus no 
treatment ranged from c46,683 to c58,282. Multiple deterministic sensitivity analyses 
(SA) were performed. The main driver of CE was the efﬁ cacy of denosumab; when it 
